
CRISPR Therapeutics (NASDAQ:CRSP) has outperformed the market over the past 5 years by 14.31% on an annualized basis.
Buying $1,000 In CRSP: 5 years ago, an investor could have purchased 54.26 shares of CRISPR Therapeutics at the time with $1,000. This investment in CRSP would have produced an average annual return of 28.1%. Currently, CRISPR Therapeutics has a market capitalization of $4.69 billion.